Encounter 38 · 38 of 42 · September 1960 – March 1962
Not yet
In 1960 a new FDA reviewer was given a sedative already sold in other countries. The file did not contain what she needed. She would not sign. She did not yet know the word the German clinics would later use.
Food and Drug Administration, Washington, D.C.
The folder is closed. Notice that before any medal.
What they knew
- The law then let a drug proceed if the FDA did not object within a set time. Silence was a kind of yes.
- The application’s safety evidence was thin. Chronic toxicity data were not what she would have required of a chemical meant for pregnant women.
- The company wanted a signature. Representatives came back.
What they could not know
- Whether the drug was dangerous, or merely poorly documented.
- What a delay would do to her new post.
- Whether a pattern of harm would appear only after approval.
The situation
Frances Oldham Kelsey, a Canadian-born physician and pharmacologist, joined the U.S. Food and Drug Administration in 1960. One of her first assignments was New Drug Application 12-611: Kevadon, Merrell’s name for thalidomide, already marketed in Canada, Britain, Germany, and elsewhere as a sedative, including for morning sickness.
A motivational telling would make her a prophet who saw phocomelia from the first page. She did not. She saw an inadequate file. Stopping, here, was a refusal to treat other countries’ marketing as evidence. The later catastrophe abroad confirmed the caution. It did not create it. The work was ordinary: a letter, a clock, another letter. That is what a signature is for, if waiting is the only method you have.
Who bears the downside if she is wrong in either direction: if she approves a poison, bodies; if she withholds a useful sedative, discomfort, and a company’s quarter. She chose the side that could still wait. The children who were not born into the American mass-market did not get a vote. Neither did the children in Germany and Britain who already had.
This Guide already holds a night when engineers recommended that Challenger not fly, and were reversed. Kelsey’s no was not reversed. The difference is not character. It is who had the last piece of paper.
What was at stake
Women who would take a pill if it were approved, and children who could not consent. Kelsey’s job was also on the table. Those are not similar stakes.
The next move
She withheld approval and asked for better evidence. Each time the clock ran down she sent another letter, resetting it. A British report of peripheral neuropathy arrived as a further reason not to hurry. She still did not have the birth-defect paper in hand when she first said no.
What they had
- A statute that made delay a method
- A pharmacologist’s suspicion of missing numbers
- Letters instead of a press conference
- No authority that looked like a hero’s
What didn’t work
Merrell’s claim that a drug sold abroad was therefore finished science. The investigational samples the company had already scattered to American doctors. some U.S. births were affected anyway.
What happened
In March 1962 Merrell withdrew the application. In August President Kennedy gave Kelsey the President’s Award for Distinguished Federal Civilian Service. The Kefauver–Harris Amendments that autumn required proof of safety and efficacy before marketing. Those later sentences were not in the 1960 folder. The folder said: not yet.
What is a signature worth if waiting is the only method you have?
Private. No one else will see it.